This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
Overview
nmCRPC
mHSPC
About NUBEQA® (darolutamide) Overview
Efficacy that doesn't compromise your patient's QoL
For adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
Introducing NUBEQA (darolutamide)
Delay metastases. Extend survival. Maintain your patient’s QoL
Extend survival. Maintain your patient’s QoL
PP-NUB-GB-2217 | March 2025
- Referencesexpand_less
- 1Smith MR et al. N Engl J Med. 2022;386(12):1132–1142.
- 2Fizazi K et al. N Engl J Med. 2020;383:1040–1049.
- 3NUBEQA (darolutamide) Summary of Product Characteristics.